This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

China's countermeasures remain in place against US fentanyl-related tariffs

( May 14, 2025, 09:43 GMT | Official Statement) -- MLex Summary: China's countermeasures — comprising tariff and non-tariff measures — implemented against two rounds of US' fentanyl-related tariffs still "remain in effect," Foreign Ministry spokesman Lin Jian said at today's press conference. The US applied a 10 percent punitive tariff on China in February, later hiking it to 20 percent in March. In response, Beijing levied additional tariffs of 10–15 percent on selective US imports such as coal, liquefied natural gas, crude oil, agricultural machinery, large-displacement vehicles, pickup trucks and agricultural products; while also imposing export controls on key minerals like tungsten and tellurium; designating certain US entities to its unreliable entity list; and initiating an antitrust probe against Google. The excerpt of the transcript follows:...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections